罗库溴铵 - 舒更葡糖用于治疗抗精神病药恶性综合征中的电休克治疗管理：一例报告

Rocuronium-sugammadex for electroconvulsive therapy management in neuroleptic malignant syndrome: A case report.

作者信息

Casas Reza P, Gestal Vázquez M, Outeiro Rosato Á, López Álvarez S, Diéguez García P

机构信息

Servicio de Anestesiología, Reanimación y Terapéutica del Dolor, Hospital Abente y Lago, Complexo Hospitalario Universitario A Coruña, A Coruña, España.

出版信息

Rev Esp Anestesiol Reanim. 2017 Feb;64(2):105-107. doi: 10.1016/j.redar.2016.04.006. Epub 2016 Jul 15.

DOI:10.1016/j.redar.2016.04.006

PMID:27424873

Abstract

Neuroleptics are a group of drugs widely used in the treatment of psychotic symptoms. Among their adverse effects is the ability to trigger a neuroleptic malignant syndrome (NMS). The diagnosis of NMS is determined by exclusion, and its initial therapeutic management should be the withdrawal of neuroleptics, the administration of benzodiazepines, and electroconvulsive therapy (ECT). ECT is an effective treatment in these patients, and in those cases with a poor response to treatment with antipsychotic drugs. A review is presented on the treatment options and anaesthetic implications of ECT used to handle a patient diagnosed with paranoid schizophrenia in the context of NMS.

摘要

抗精神病药物是广泛用于治疗精神症状的一类药物。其不良反应之一是能够引发抗精神病药物恶性综合征（NMS）。NMS的诊断是通过排除法确定的，其初始治疗管理应包括停用抗精神病药物、给予苯二氮䓬类药物和电休克治疗（ECT）。ECT对这些患者以及对抗精神病药物治疗反应不佳的患者是一种有效的治疗方法。本文综述了在NMS背景下用于治疗被诊断为偏执型精神分裂症患者的ECT的治疗选择和麻醉影响。